Company / Total Assets
NeoGenomics Laboratories, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$1.4B
FY2025
5-year range
$1.4B / $1.9B
FY2021-FY2025
Trend
-17.0%
vs FY2024
Sector context
#106 of 161
Health Care
What the data says
At $1.4B, NeoGenomics Laboratories, Inc.'s total assets ranks #106 of 161 in the Health Care sector. Total Assets has declined for 4 consecutive years, from $1.9B in FY2021 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +6.6%.
Declined from $1.7B to $1.4B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -7.9%
- 5-Year CAGR
- +6.6%
- 10-Year CAGR
- -
Sector benchmark
#106 of 161 in Health CareTop 66% of 161This company $1.4B Sector average $14.8B
▼
-90.8% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s total assets has declined for 4 consecutive years.
- 5-year CAGR of +6.6%, indicating consistent growth.
- In FY2025, total assets decreased 17.0% year-over-year.
- Ranks #106 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | -17.0% |
| FY2024 | $1.6B | -2.6% |
| FY2023 | $1.7B | -3.4% |
| FY2022 | $1.7B | -6.9% |
| FY2021 | $1.9B | +89.2% |
| FY2020 | $988.3M | +39.3% |
| FY2019 | $709.5M | +40.5% |
| FY2018 | $505.0M | +46.6% |
| FY2017 | $344.5M | +2.2% |
| FY2016 | $337.1M | -4.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026